Update of PDE5 inhibitors as treatment of ED.
- Author:
Yong-ning LU
1
;
Bin CHEN
Author Information
1. Department of Urology, Shanghai Institute of Andrology, Renji Hospital Affiliated to Shanghai Second Medical University, Shanghai 200001, China.
- Publication Type:Journal Article
- MeSH:
Erectile Dysfunction;
drug therapy;
Humans;
Male;
Phosphodiesterase Inhibitors;
adverse effects;
therapeutic use;
Piperazines;
adverse effects;
therapeutic use;
Purines;
adverse effects;
therapeutic use;
Sildenafil Citrate;
Sulfones;
adverse effects;
therapeutic use
- From:
National Journal of Andrology
2005;11(7):552-555
- CountryChina
- Language:Chinese
-
Abstract:
Erectile dysfunction is a common ailment in middle-aged and old men. The management of ED has entered a new stage since sildenafil was used to treat ED in 1998. Sildenafil became the first-line treatment for its efficacy and safety. In recent years, new PDE5 inhibitors--vardenafil and tadalafil came into market in succession, providing more options available for oral therapy. This review is about the development of preclinical and clinical medicine research on the three PDE5 inhibitors, and provide information for clinical choices.
